Navigation Links
Mylan Names John Thievon President of Dey Pharma
Date:12/12/2011

PITTSBURGH, Dec. 12, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the appointment of John Thievon as president of Dey Pharma, L.P., Mylan's fully integrated specialty pharmaceutical business.

Thievon has more than 20 years of professional experience in strategic product launches, marketing, commercialization, sales penetration and distribution leadership. Most recently, he served as president and chief executive officer of MiddleBrook Pharmaceuticals. In this capacity, he helped build the company from an 18-person start-up to a 450-person organization before the company's assets were acquired by Victory Pharma.

Prior to leading MiddleBrook Pharmaceuticals, Thievon was executive vice president of commercial operations for Adams Respiratory Therapeutics over a nine-year span. He built Adams' marketing platform and led the launch of Mucinex®, growing it to a $450 million brand before the company was sold to Reckitt Benckiser.

Mylan's President Heather Bresch commented: "I am extremely pleased to welcome John as our new leader of Mylan's specialty business. John's extensive experience growing a branded pharmaceutical business from the ground up and proven track record launching highly successful pharmaceutical brands, like Mucinex, is invaluable as we continue to build on our specialty business. Dey has been and continues to be a very valuable asset and important growth driver for Mylan, evidenced by the strong performance of this business. John's appointment demonstrates our continued commitment to invest in Dey and strengthen what we have in place in order to support the continued success of this business into the future."

Thievon commented: "I am thrilled to be joining Mylan as Dey's new president. I am excited about the potential of Dey's existing product portfolio and the introduction of new products. The momentum behind this business is a result of impressive execution by the strong team already in place at Dey and I look forward to working alongside this team to maximize Dey's growth potential."

Thievon began his career as a management trainee and sales representative for Ortho Pharmaceuticals after graduating with a bachelor's degree in marketing from Pace University, New York, N.Y. He subsequently spent four years at IMS Health, where he developed his expertise in leveraging market data to generate informed and innovative business plans.

About Mylan
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  The Baylor ... received an in-kind gift from ... VeinViewer® Vision vein finder for the nursing ... students as they learn how to start ... with traditional technique. ...
(Date:2/10/2016)... VIEW, Calif. , Feb. 10, 2016 ... of a synergistic confluence of various technologies ... value propositions, previously unavailable. These opportunities create ... and convergence, in turn, drives the development ... entrepreneurial scenario is characterized by technology convergences, ...
(Date:2/10/2016)... 10, 2016 /PRNewswire/ - The President of New Venture ... release of an anti-radiation product from their Research ... in the treatment of cancer using radiation and ... assist in the healing of radiation burns, even ... protect only the healthy cells from radiation damage. ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
(Date:2/10/2016)... Florida (PRWEB) , ... February 10, 2016 , ... ... weather-forecasting company is unveiling its revolutionary new 2.0 version at the International Roofing ... has “put the power of the world's most advanced weather technology in the ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... (VRI) within Healthcare, recently partnered with Heart City Health Center to ... nearly 23 years, Heart City Health Center has provided the Elkhart community with ...
(Date:2/10/2016)... Huntington, NY (PRWEB) , ... February 10, 2016 ... ... web-based compliance tracking solution, The Guard, to associations of medical professionals throughout the ... HIPAA compliance, including security risk assessments, policies and procedures, employee training, regulatory updates, ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... Emergency ... be harder to find. Unfortunately, this can leave patients with dental emergencies at risk ... , is now offering emergency dental care. , Common dental emergencies include:, ...
Breaking Medicine News(10 mins):